Don't Miss


Payer pricing and reimbursement strategies for neurological therapies

Despite wide unmet need across a number of neurological conditions no really high impact breakthrough therapies have come to the market in recent years. The price for generics has continued to rise—sometimes dramatically—and the broad upward trend in new drug pricing shows no sign of abating. Payers want effective therapies and evidence of utility, and many question the value of new drugs that offer only marginal clinical benefits. What are cost-conscious payers doing to manage the escalating cost of neurological disease treatments? To examine approaches to pricing and reimbursement (P&R) in multiple sclerosis, epilepsy, migraine, Alzheimer's disease and Parkinson's disease we interviewed leading US and European payers. In Pricing and Reimbursement in Neurology: Payer Views they examine how price trends are affecting patient access, the impact of COVID-19, and they reveal the strategies they employ for formulary placement, tiering, reimbursement and pricing. Find out more >>

Insight, Analysis and Views

GSK's Nucala cleared in US for hypereosinophilic syndrome

My News

Upgrade your subscription to get more features!

Conference News

Latest News

StoryWatch